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ABSTRACT 
Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune 
disease. Emerging data suggests that T helper 17 (Th17) cells play a pathogenic role in 
SLE and the increased number of these cells correlates with disease activity. In recent
years, 1α, 25-dihydroxyvitamin D3 (1,25VitD3) has been considered as an 
immunomodulatory factor. Objective: To investigate the effect of 1,25VitD3 on Th17 
cells and on the expression of related cytokines in SLE patients. Method: Thirty SLE 
patients (newly diagnosed or in remission) were sampled for 10 ml whole blood to 
isolate peripheral blood mononuclear cells (PBMCs) using Ficoll-Hypaque density 
gradient centrifugation. Isolated cells were cultured in the presence and absence of 50 
nM 1,25VitD3. After incubation, cells were harvested and stimulated for 4-5 hours with 
phorbol myristate acetate (PMA) and ionomycin in the presence of brefeldin A. IL-17 
secreting cells were analyzed by flowcytometry. RNA was extracted from cultured 
cells, cDNA was synthesized, and the expression levels of IL-6, IL-17, IL-23 and TGF­
β genes were assessed by real-time PCR. Results: The percentage of Th17 cells 
(CD3+CD8- IL-17+ T cells) decreased significantly in 1,25VitD3-treated cells (3.67 ± 
2.43%) compared to untreated cells (4.65 ± 2.75%) ( p=0.003). The expression of TGF­
β up regulated (1.38-fold) and the expression of IL-6 (50%), IL-17 (27%) and IL-23 
(64%) down regulated after 1,25VitD3 treatment. Conclusion: This study showed that 
1,25VitD3 modulates Th17 related pathways in SLE patients and revealed the
immunomodulatory effect of 1,25VitD3 on the Th17 mediated autoimmunity. 
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INTRODUCTION 
Interleukin17 (IL-17) producing T cells are functionally distinct from T helper-1 (Th1) 
and T helper-2 (Th2) cell lineages, though they have recently been classified as a new 
subset of effector TCD4+ cells known as T helper17 (Th17) cells. Several cytokines are 
involved in the promotion and development of Th17 cells including IL-1β, IL-6, IL-21, 
IL-23 and TGF-β (1,2). Each of these cytokines have different roles in optimizing the
differentiation and regulation of Th17 cells (3,4).Th17 cells produce IL-17A (IL-17), 
IL-17F, IL-21 and IL-22 cytokines (5). It is proposed that Th17 cells produce strong 
proinflammatory cytokines and play an important role in the development of systemic 
lupus erythematosus (SLE). 
SLE is a multifactorial autoimmune disease in which auto reactive T cells become 
activated against mainly nuclear antigens. Subsequently, B cells start producing 
autoantibodies. The major pathologic finding in SLE is immune complex deposition. 
SLE related clinical manifestations are different depending on the tissue involvement 
(6). Several independent studies have shown that IL-17 producing cells or CD4+ T cells 
expressing Th17 related chemokine receptors (CCR4 and CCR6) are increased in lupus.
Increased frequency of these cells and higher production of IL-17 are correlated with 
disease activity (7-9). Other studies indicated that imbalance between T regulatory 
(Treg) and Th17 cell subsets is responsible for some inflammatory responses in SLE. 
Moreover, exacerbation of symptoms in lupus may be related to increased population of 
Th17 cells and IL-17 versus decreased population of regulatory T cells (10-12). 
The exact cause of SLE is unknown (6), but environmental factors are highly suspected 
of being conducive to the preparation of conditions for the development of the disease. 
Vitamin D (VitD3) deficiency was recently believed to be a contributing factor in SLE 
development (13,14).VitD3 deficiency is common in SLE, however, the relationship 
between low VitD3 levels and disease activity is controversial (15-16). Although it has
been revealed that 1,25VitD3 inhibits conversion of CD4+ T cells to Th17 cells (17), the 
immunomodulatory influence of 1,25VitD3 on Th17 cells is still under investigation. 
Cytokine milieu could affect T helper cells conversion toward regulatory (Tregs) or
Th17 cells (1,3). TGF- and IL-6 have play roles in the development of these cells; 
increased presence of TGF- in the absence of IL-6 promotes T helper cells 
differentiation toward generation of regulatory T cells, while presence of TGF- in
concert with IL-6 induces the generation of Th17 cells (18-19). In the present study, by 
evaluating the influence of vitamin D on the expression of IL-6 and TGF- we aimed to 
estimate the mechanisms by which 1,25VitD3 influences production and function of 
Th17 cells and related cytokines in systemic lupus erythematosus patients. 
MATERIALS AND METHODS  
Study Population and Cell Preparation. In this study, 30 patients with SLE (27 
women and 3 men) were enrolled based on the 1997 revised American College of 
Rheumatology (ACR) diagnostic criteria. Patients were newly diagnosed and had not 
yet received any medications (12 new cases) or were treated by a maximum dose of 5 
mg per day of prednisolone and/ or a dose of 200 mg hydroxychloroquine (18 patients).
After obtaining informed consent from patients, 10 ml of peripheral venous blood was 
sampled from each patient. Peripheral blood mononuclear cells (PBMCs) were isolated 
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using Ficoll-Hypaque (Cedarlane, Hornby, Ontario, Canada) density gradient
centrifugation and after washing with PBS, cells were re-suspended in 1 ml RPMI 1640 
medium (Biosera, East Sussex, UK). 
In newly diagnosed patient’s blood was taken before starting treatment. In patients who 
were in remission only the patients who took only a maximum dose of 10 mg/day of 
prednisolone and/or 10 mg/kg/day of hydroxychloroquine were included in the study 
The study was approved by the ethics committee of Mashhad University of Medical 
Sciences, and written informed consent was obtained from all patients before taking 
blood. 
Optimization of 1,25VitD3 Concentration for Treatment. In our lab we performed
some serial studies to explore the effects of vitamin D on different features of the 
immune responses in systemic lupus erythematosus patients. In order to determine the 
optimum concentration of 1,25VitD3 (Sigma-Aldrich, St. Louis, MO, USA) in the
culture medium, vitamin D concentration was first optimized. In the set up process we
used different concentrations of vitamin D (10, 50 and 100 nM) according to some
previous studies on this purpose (18-20) and studied the following properties: 
A. Toxicity effects of different concentrations of vitamin D (by MTT method) on the 
PMBCs of newly diagnosed SLE patients. 
B. Apoptotic effects of different concentrations of vitamin D (using Annexin V/PI by 
Flowcytometry) on the PMBCs of newly diagnosed SLE patients. 
C. Immune modulatory effects 	of different concentrations of vitamin D by 
determining regulatory T cells using flowcytometry (Figure 1).  
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Figure 1. Determination of the optimum concentration of vitamin D. To determine the optimum 
concentration of vitamin D we cultured the PBMCs of 3 new case lupus patients with 10, 50 and
100 nM of vitamin D. The number of Regulatory T cells in each patient was evaluated in the
cells treated with and without vitamin D by flow cytometer using anti-CD4, anti-CD25 and anti­
Foxp3. 50 nM was chosen as the optimum concentration of vitamin D in this study. 
After that 50 nM concentration was selected as the best concentration of vitamin D for 
our further studies. 
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In the set up we preferred to study the cells of newly diagnosed patients to remove the 
probable interference of the factors other than vitamin D. It should be mentioned that in 
lower doses there was not any immunomodulatory effect on selected cells. 
PBMCs Culture in the Presence of 1,25VitD3. PBMCs were cultured in 24 well 
plates under sterile conditions (2 ×106 cells/well) in the presence and absence of 50 nM 
of 1,25VitD3 in a total volume 1 ml RPMI 1640 supplemented with 10% heat 
inactivated Fetal Calf Serum (FCS; Gibco Invitrogen, Paisley, U.K). Cells were 
incubated overnight at 37°C in a 5% CO2, humidified incubator. 
Cell Stimulation for Intracellular Cytokine Production. Some of the cells were 
harvested from the culture medium (cells with and without 1,25VitD3).The cells (1×106) 
were cultured with 50 ng/ml PMA and 1µg/ml ionomycin (eBioscience, San Diego, 
CA, USA) for 4 to 5 hours in the presence of brefeldin A (eBioscience, USA) at 37°C 
and 5% CO2, for intracellular cytokine production. 
Surface Antigens and IntracellularCytokine Staining. After stimulating the cells for 
4 to 5 hours, cell surface staining was performed with anti-CD3 conjugated with PE­
Cy5 and anti-CD8 conjugated with FITC ( BD Biosciences, San Diego, CA, USA). The 
cells were fixed/permeabilized using the fixation/permeabilization and permeabilization 
buffers according to the manufacturer’s protocol (eBioscience, San Diego, CA, USA) 
and Intracellular staining was performed using anti-IL17 conjugated with PE or isotype 
control (BD Biosciences, San Diego, CA, USA). 
Figure 2. Flowcytometric analysis of a SLE patient sample. (A) Isotype control. (B) The 
percentage of Th17 cells in PBMCs cultured in the absence of 1,25 VitD3. (C) The percentage 
of Th17 cells in PBMCs cultured in presence of 50 nM 1,25 VitD3. The percentage of IL-17 
producing cells shows a decrease in the 1,25 VitD3-treated cells compared with untreated cells. 
Upper left quadrant shows percentage of IL-17 secreting cells.
Flowcytometric Analysis. The stained cells were acquired on a BD FACSCalibur 
system. The collected data were analyzed using the CellQuest software (Becton 
Dickinson, San Jose, CA, USA). To identify Th17 cells, lymphocytes and then CD3+ 
cells were gated and the percentage of TCD3+ CD8- IL-17+ cells were obtained in a 
CD3+ Gate (Figure 2). 
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RNA Extraction and cDNA Synthesis. 1× 106 of the cultured cells were selected for
RNA extraction. Total RNA was extracted using Tripure reagent according to the
manufacturer's instructions (Roche Diagnostics GmbH, Mannheim, Germany). Integrity 
and purity of RNA was confirmed by the ratio of relative absorbance at 260:280 OD 
using a spectrophotometer as well as electrophoresis in agarose gel. One µg of total 
RNA was reverse transcribed to cDNA using RevertAid™ M-MuLV Reverse 
Transcriptase and random hexamer primers according to the manufacturer’s
recommendations (MBI Fermentas, St. Leon-Rot, Germany). 
Table 1. Probes and primers used in this study.
Name Sequence bp
IL6F* 5′- CTTCGGTCCAGTTGCCTTCTC-3′ 21
IL6R** 5′- ATTCGTTCTGAAGAGGTGAGTGG-3′ 23
IL6P*** 5′-6FAM CTGCTCCTGGTGTTGCCTGCTGCC TAMRA-3′ 24
IL-17F 5′- CAGCAAGAGATCCTGGTCCTG-3′ 21
IL-17R 5′- GACAATCGGGGTGACACAGG -3′ 20
IL-17P 5′-6FAM AGCCTCCACACTGCCCCAACTCCT TAMRA-3′ 24
IL23F 5′- ACACATGGATCTAAGAGAAGAG-3′ 22
IL23R 5′- GCAGAACTGACTGTTGTC-3′ 18
IL23P 5′-6FAMTCACAGCCATCTCCACACTGG TAMRA-3′ 21
TGF-βF 5′- GCAACAATTCCTGGCGATACC-3′ 21
TGF-βR 5′- GCCCTCAATTTCCCCTCCAC-3′ 20
TGF-β  5′-6FAM CTCAACCACTGCCGCACAACTCCG TAMRA-3′ 24
GAPDHF 5´-AGCCGGGCATGTTCTTCAAC-3´ 20
GAPDHR 5´-AGGGAGCTTCACGTTCTTGTATC-3´ 23 
GAPDHP 5´-CGGAGCTGGACCTGACCTACGGCA- 3´ 24
*Forward primer **Reverse primer ***Probe
Probe and Primer Design. Primer and Taq Man probe sequences for all targets (IL-6, 
IL-17, IL-23 and TGF-β) were designed using Beacon designer version 7.9 software.
Exon–intron junctions (from www.ensembl.org/index.html) were used to design primers.
Then designed primers were blasted at the National Center for Biotechnology 
Information database (NCBI) to ensure the specificity of the primers. Glyceraldehyde 3­
phosphate dehydrogenase (GAPDH) housekeeping gene was used as a reference gene
for normalization of the cDNA load. Probe and primer sequences used for amplification 
are available in Table 1.  
Iran.J.Immunol. VOL.12 NO. 2 June 2015 86 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
   
  
  
  
  
  
  
Reihani H, et al. 
Real Time PCR and Analysis of Gene Expression. Quantitative Real time PCR was 
performed using Premix Ex Taq (Takara Bio, Otsu, Shiga, Japan) and specific primers
on a Rotor-Gene® Q system (QIAGEN, Germany).  
After the completion of the cycles, the data were analyzed using the same system 
software. 2 –ΔΔCT (Livak) Method was used for the relative quantification of the target 
gene expression in each sample (21).The data were normalized to GAPDH as reference 
gene and Relative quantification of target gene in 1,25VitD3 treated sample was
expressed as a fold change compared to the untreated sample.  
ΔCT treated=CT (target, treated)-CT (reference, treated)
CT untreated=CT (target, untreated)-CT (reference, untreated)Δ
ΔΔCT=ΔCT treated-ΔCT untreated
Normalized expression ratio =2 –ΔΔCT
Statistical Analysis. IBM SPSS Statistics version 21 software was used for statistical 
analysis. Quantitative data were reported as Mean ± SD and the difference between the 
two groups was determined using the parametric paired t-test. P value <0.05 was 
considered statistically significant.  
RESULTS 
Demographic, Clinical and Laboratory Data. From 30 cases with SLE (27 women 
and 3 men), 12 patients were new cases (sampling performed before medical therapy)
and 18 patients were in remission. The mean duration of disease in old cases was 5.2 ± 
2.8 years. The mean age of the participants was 34.45 ± 9.33 years.  
Table 2. Collective demographic and serologic characteristics of the SLE 
patients in this study.
No of SLE patients 30
No of female patients 27
No of male patients 3 
No of newly diagnosed patients 12
No of in remission patients 18
Mean age at time of study 34.45 ± 9.33 years
Positive Anti-dsDNA 88.4 % 
C3 deficiency 23.0 %
C4 deficiency 26.9 %
Leucopenia  37.9 %
Lymphopenia 24.1 %
Thrombocytopenia 6.89 %
Proteinuria more than 500 mg/day 20.6 %
Iran.J.Immunol. VOL.12 NO. 2 June 2015 87 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Vitamin D3 modulates Th17 cells 
Table 2 shows the important demographic data of patients. Moreover, in the newly 
diagnosed patients the three main clinical presentations were arthritis (70.7%), nephritis 
(20%), and skin involvement (33.6%). 
1,25VitD3 Decreases Percentage of Th17 Cells in Vitro. To assess the effect of 
1,25VitD3 on the number of IL-17 producing cells, after cell culture and stimulation 
with PMA and ionomycin in the presence of brefeldin A, cells were analyzed using 
flowcytometry. Percentage of TCD3+ CD8- IL-17+cells in the PBMCs cultured in the 
presence of 1,25VitD3 significantly decreased (3.67 ± 2.43%) compared with PBMCs
cultured in the absence of 1,25VitD3 (4.65 ± 2.75%; p=0.003)(Figure 3). 
Figure 3. Percentage of Th17 cells in PBMCs of SLE patients, cultured in the presence of 50
nM 1,25VitD3 showed a statistically significant decrease compared with PBMCs cultured in the
absence of 1,25VitD3.
1,25VitD3 Modulates the Expression of Th17 Related Cytokine Genes in Vitro. We
studied whether the expression of Th17 related cytokine genes could be regulated by 
1,25VitD3 in vitro. After real time PCR, relative expression levels (Relative 
Quantification) of IL-6, IL-17, IL-23 and TGF-β genes were calculated using the 2 –ΔΔCT 
method. With evaluation of gene expression level in PBMCs cultured in the presence 
and absence of 1,25VitD3, the relative expression level of TGF-β up regulated (1.38 
fold) and the relative expression levels of IL-6 (50%), IL-17 (27%) and IL-23 (64%) 
down regulated after 1,25VitD3 treatment (Figure 4). 
Comparison of the Effects of 1,25VitD3 in Newly Diagnosed and in Remission SLE 
Patients. 1,25VitD3 treatment decreased the percentage of Th17 cells in PBMCs of 
both newly diagnosed and in SLE patients who were in remission, this decrease was
significant in patients who were in remission (p=0.008) (Figure 5).  
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Figure 4. Relative expression levels of genes after treatment with 50 nM of 1,25VitD3. The 
relative expression of IL-6(50%), IL-17(27%), and IL-23(64%) down regulated and the relative
expression of TGF-β (1.34-fold) up regulated after 1,25VitD3 treatment. Relative quantification 
of cytokines was as follows: IL-6 (0.50 ± 0.07), IL-17 (0.73 ± 0.02), IL-23(0.36 ± 0.09) and TGF­
β (1.38 ± 0.24) fold. 
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Figure 5. Percentage of Th17 cells in PBMCs of newly diagnosed and in remission SLE 
patients, cultured in the presence and absence of 50 nM 1,25VitD3. 
1,25VitD3 treatment in newly diagnosed SLE patients increased the ex ression level of
TGF- significantly (2.11 fold) in comparison with the in remission patients (1.04 fold) 
(p=0.008). In SLE patients who were in remission 1,25VitD3 treatment decreased the
expression level of IL-6 significantly (0.85 fold) compared to newly diagnosed patients 
(0.36 fold) (p=0.023).
 
Difference in the expression levels of IL-17 and IL-23 after 1,25VitD3 treatment was 

not significant between newly diagnosed and in remission SLE patients (Figure 6).
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Figure 6. Relative expression levels of genes after treatment with 50 nM of 1,25VitD3 in newly 
diagnosed and in SLE patients who are in remission. In SLE patients who are in remission 1,25
VitD3 treatment decreased the expression level of IL-6 significantly compared to newly
diagnosed patients (p=0.023). 1,25 VitD3 treatment in newly diagnosed SLE patients increased
the expression level of TGF- significantly in comparison to in remission patients (p=0.008). 
Difference in the expression levels of IL-17 and IL-23 after 1,25VitD3 treatment was not 
sinificant between newly diagnosed and in remission SLE patients.
DISCUSSION 
The main outcome of this study was that the active metabolite of vitamin D (1, 
25(OH)D) strongly modulates Th17 cell-mediated immune responses. As a result, 1, 25 
VitD3 can inhibit Th17 cells through different mechanisms in both gene expression and 
cytokine expression pathways. 
1,25VitD inhibits differentiation and maturation of dendritic cells as well as B cells. 
1,25VitD3 suppresses T cell proliferation and shifts Th1 cell phenotype to Th2 and also 
Th17 cell phenotype to Treg. To sum up, 1,25VitD3 changes inflammatory milieu to 
anti-inflammatory ones (22,23). However, there is still little knowledge about the 
molecular mechanisms underpinning the effects of 1,25VitD3 on the immune system.  
In this study, 1,25VitD3 significantly decreased the percentage of Th17 cells in vitro, 
which is consistent with previous studies. A Study demonstrated that culturing mouse
cells in the presence of 1,25VitD3 reduced the number of IL-17 producing cells from 11 
to 7% in Th17-inducing conditions and from 14 to 7% in Treg-inducing conditions (24). 
Direct regulatory effects of 1,25VitD3 on differentiation of T cells and inhibition of the 
generation of Th17 cells in vitro depends on vitamin D receptors (VDRs) expressed in 
the TCD4 cells and dose of 1,25VitD3 (25). 1,25VitD3 modulates development of 
Th17, Th1 and Th9 cells through inhibitory actions on these inflammatory cells and 
advances regulatory T cell development (26). 
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Some studies have shown that the influence of 1,25VitD3 on Th17 cells can be 
conducted by two mechanisms. The first one is direct inhibition of IL-17 production 
from TCD4 cells; the second one is modulating cytokine milieu of IL-1, IL-6, TGF-β1, 
TNF-α and IL-23 for indirect induction of Th17 cells (27). 
The present study showed that expression level of TGF-β is up regulated and conversely 
IL-6, IL-17 and IL-23 are down regulated relatively by 1,25VitD3 in vitro. These results 
are in agreement with previous reports about inhibitory effects of 1,25VitD3 on Th17­
related cytokines. There are some other data on inhibitory effects of 1,25VitD3 on IL­
17A production in rheumatoid arthritis, multiple sclerosis, and mouse model of MS 
(Experimental Autoimmune Encephalomyelitis) (28).  
1,25VitD3 supresses IL-6 expression (29). IL-6 is a key cytokine for B cell 
differentiation into plasma cells. Linker-Israeli et al. in their study specified that 
reduced IgG production in SLE in the presence of 1,25VitD3 is mediated by reducing 
IL-6 (30). 
It has been found that imbalance between Th17 and Treg cells is a part of SLE 
pathogenesis. IL-6 plays a pivotal role in the interaction between Th17 and Treg and 
interacts with TGF-β to promote the development of Th17 cells (11). 1,25VitD3 and 
VDRs are a component of Th17/iTreg axis regulators. In the absence of 1,25VitD3 or its 
receptor, TCD4 cells produce more IL-17 (24). Mahon et al. proposed that 1,25VitD3 
supplementation increases the serum levels of circulating TGF-β (31). Another study 
showed that 1,25VitD3 increases the expression level of TGF-β in the mouse model 
(32). In aggregate, it seems that 1,25VitD3 promotes Th17 cells to Treg cells by 
decreasing IL-6 and TGF-β. The current study also suggested that 1,25VitD3 reduces 
IL-6 gene expression in contrast to its effect on TGF- β gene. 
IL-23/IL-17 axis is also important in the pathogenesis of SLE and lupus nephritis
(33,34). One study showed that T cells cultured by TGF-β1 and IL-6 are not pathogenic
in the absence of IL-23. Our result was in accordance with other studies in which the
inhibitory effect of 1,25VitD3 on IL-23 production was documented (35).  
The current study was not without limitations,however. Sample size was relatively 
small, but we enrolled 12 new cases who did not receive any medications. Moreover, 
other patients were treated with a minimum dose of immunomodulatory medications 
without any immunosuppressive drug. Assessment of the effects of 1,25VitD3 on Th17 
cells in both gene expression and cytokine production levels using sensitive techniques 
can be considered a strong point in the scientific merit of this study. 
In conclusion, our data showed that 1,25VitD3 effectively modulates Th17 cell-
mediated cytokines. Moreover, an optimal immunomodulatory dose of 1,25VitD3 
without its potential side effects, especially hypercalcemia, is still a matter of debate 
(36). This study suggested that 50 nM of 1,25VitD3 has significant suppressive effects 
on Th17 cells and related cytokines. Therefore, further research on the mechanisms
underlying the effects of 1,25VitD3 on cells involved in autoimmune disease along with 
the determination of effective doses will be warranted to designe therapeutic strategies
to prevent and treat Th17 cell-mediated autoimmune diseases.  
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